4 Biotechnology Stocks to Buy Now

by Portfolio Grader | October 31, 2012 9:00 am

4 Biotechnology Stocks to Buy Now

This week, four Biotechnology stocks are improving their overall rating on Portfolio Grader[1]. Each of these rates an “A” (“strong buy”) or “B” overall (“buy”).

Gentium (NASDAQ:GENT[2]) is bettering its rating of C (“hold”) from last week to a B (“buy”) this week. Gentium is a biopharmaceutical company focused on the discovery, research, development, and manufacture of drugs for the treatment and prevention of a variety of vascular diseases and conditions related to cancer and cancer treatments. In Portfolio Grader’s specific subcategory of Earnings Revisions, GENT also gets an A. Shares of GENT have increased 10.7% over the past month, better than the 4.1% decrease the Nasdaq has seen over the same period of time. Shares of the stock have been trading at an exceptionally rapid pace, up fourfold from the week prior. For more information, get Portfolio Grader’s complete analysis of GENT stock[3].

Achillion (NASDAQ:ACHN[4]) shows solid improvement this week. The company’s rating rises from a C to a B. Achillion focuses on the discovery, development and commercialization of innovative treatments for infectious diseases. For more information, get Portfolio Grader’s complete analysis of ACHN stock[5].

Discovery Laboratories (NASDAQ:DSCO[6]) earns a B this week, jumping up from last week’s grade of C. Discovery Laboratories is a biotechnology company focused on developing products for the treatment of respiratory disease. Shares of the stock have been trading at an exceptionally rapid pace, up twofold from the week prior. For more information, get Portfolio Grader’s complete analysis of DSCO stock[7].

BioMimetic Therapeutics (NASDAQ:BMTI[8]) improves from a C to a B rating this week. BioMimetic Therapeutics engages in the development and commercialization of regenerative protein therapeutic products primarily used for bone and tissue regeneration, repair and healing of musculoskeletal injuries, and conditions affecting bones, tendons, ligaments, and cartilage. For more information, get Portfolio Grader’s complete analysis of BMTI stock[9].

Louis Navellier’s proprietary Portfolio Grader[1] stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here[10].

Endnotes:
  1. Portfolio Grader: http://navelliergrowth.investorplace.com/portfolio-grader/
  2. GENT: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=GENT
  3. For more information, get Portfolio Grader’s complete analysis of GENT stock: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=GENT
  4. ACHN: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=ACHN
  5. For more information, get Portfolio Grader’s complete analysis of ACHN stock: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=ACHN
  6. DSCO: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=DSCO
  7. For more information, get Portfolio Grader’s complete analysis of DSCO stock: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=DSCO
  8. BMTI: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=BMTI
  9. For more information, get Portfolio Grader’s complete analysis of BMTI stock: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=BMTI
  10. here: http://navelliergrowth.investorplace.com/portfolio-grader/

Source URL: http://investorplace.com/2012/10/4-biotechnology-stocks-to-buy-now-gent-achn-dsco/
Short URL: http://invstplc.com/1fyuYqr